For decades, the standard clinical interpretation of patients experiencing a resurgence of distress while tapering off antidepressants has been straightforward: the underlying psychiatric "illness" is returning. This "relapse" narrative has frequently been used to justify the lifelong use of psychotropic medications. However, a groundbreaking new study is challenging this paradigm, suggesting that the majority of these symptoms are not a return of the original condition, but are instead physiological withdrawal reactions caused by the brain’s struggle to adapt to the absence of the drug.
Led by Andri Rennwald of the Zurich University of Applied Sciences, the research—currently available as a preprint—provides a quantitative estimate that shifts the responsibility from the patient’s biology to the medication’s pharmacology. The study suggests that approximately 60% of symptom increases during antidepressant tapering are attributable to withdrawal, particularly when doses drop below a specific threshold of "minimum effectiveness."
Main Facts: Redefining the Tapering Experience
The core finding of the Rennwald study is a striking correlation between dose reduction and symptom emergence. The researchers identified that clinically relevant symptom increases most frequently emerge when an antidepressant dose is reduced to below 75% of its "minimum effective dose" (MED).
The MED is defined as the lowest dose of a drug typically required to produce a therapeutic effect in most patients. According to the study, as long as a patient remains above this 75% MED threshold, the risk of symptom increase remains relatively low—and in many cases, symptoms actually continue to decrease. However, once the dosage crosses into the sub-therapeutic range, the risk of "relapse-like" symptoms spikes significantly.
The researchers used a comparative statistical model to isolate withdrawal from relapse. By comparing the rate of symptom return in patients who were not tapering (the "baseline" rate of natural fluctuation) to the rate of symptom return in those tapering at low doses, they concluded that the excess risk is almost entirely pharmacological. Specifically, they estimate that 60% of the risk of "clinically relevant intra-individual symptom increases" is attributable to withdrawal effects.
Chronology: The Evolution of the "Deprescribing" Movement
To understand the weight of this study, one must look at the trajectory of the two prominent co-authors: Michael Hengartner and Mark Horowitz. Their involvement signals a growing movement within psychiatry that seeks to correct what they describe as "evidence-biased" medicine.
The Critical Perspective of Michael Hengartner
Michael Hengartner, a professor at the Zurich University of Applied Sciences, has spent years documenting the long-term outcomes of antidepressant use. His previous research found that antidepressant use was linked to an 81% increased likelihood of worsening depression severity over time. In his book, Evidence-biased Antidepressant Prescription, Over-medicalisation, Flawed Research, and Conflicts of Interest, Hengartner argues that the benefits of these drugs are systematically overestimated while their harms are minimized by a medical establishment heavily influenced by the pharmaceutical industry.
The Personal and Professional Journey of Mark Horowitz
Dr. Mark Horowitz, a clinical research fellow in psychiatry at University College London, brings a unique perspective to the study. His interest in tapering began with his own "lived experience." After years of taking antidepressants, Horowitz attempted to stop and encountered what he described as "the most unpleasant experience of my life."
This experience led him to co-author the Maudsley Deprescribing Guidelines, a seminal text that advocates for a radical departure from traditional tapering methods. Horowitz has been a vocal critic of the American Society of Clinical Psychopharmacology (ASCP), arguing that official guidelines frequently mistake withdrawal for relapse, thereby trapping patients in a cycle of unnecessary long-term medication.
Supporting Data: Quantifying the Tapering Risk
The Rennwald study employed a longitudinal design, following 32 Swiss adults who had been on antidepressants for at least six months and had decided to discontinue their use. Symptoms were assessed at multiple intervals: before tapering, and then at two, four, six, eight, 16, and 26 weeks.
The Statistical Breakdown
The data revealed a clear "threshold effect" regarding the risk of symptom worsening:
- No Dose Reduction: 13% of intervals showed symptom worsening (natural baseline).
- Reduction Above 75% of MED: 8% of intervals showed symptom worsening (actually lower than the baseline).
- Reduction Below 75% of MED: 33% of intervals showed symptom worsening.
By subtracting the 13% baseline from the 33% risk seen at low-dose reductions, the researchers identified a 20% "excess risk." This led to the conclusion that in a group of 33 people experiencing symptoms at low doses, 20 of them (roughly 60%) are likely experiencing withdrawal, not a relapse of their original condition.
Severity and Prevalence
The study also categorized the severity of these symptoms among participants:
- 53% of participants reported worsening symptoms at some point when their dose dipped below 75% of the MED.
- 34% experienced moderate increases.
- 19% experienced severe increases.
- 22% experienced mild, subclinical increases.
These figures suggest that more than half of all patients attempting to quit antidepressants will face significant physiological challenges that could easily be misinterpreted by a physician as a return of depression or anxiety.
Official Responses and Clinical Guidance: A New Map for Tapering
Parallel to the Rennwald study, a new letter published in the African Journal of Primary Health Care & Family Medicine, authored by Mark Horowitz and T.L. Perry, provides a practical roadmap for "safe stopping." The central tenet of this guidance is that tapering must be personalized, as withdrawal reactions vary wildly between individuals.
The Risk-Stratified Approach
The authors suggest a tiered system for tapering based on the patient’s history:
- Low Risk (Short-term use of low-risk drugs): These patients should start with a 25% dose reduction, followed by 2–4 weeks of monitoring. The total discontinuation period should span 6 to 9 months.
- Moderate Risk (Months of use): These patients should start with a slower 10% reduction. The expected timeframe for discontinuation is 9 to 18 months.
- High Risk (Years of use): For long-term users, the authors recommend an ultra-slow 5% taper. These patients should expect the process to take two years or more.
Addressing Akathisia and Protracted Withdrawal
The guidelines also address some of the more severe symptoms of withdrawal, such as akathisia—a state of extreme agitation and physical restlessness. The authors advise that if akathisia occurs shortly after a dose reduction, reinstating the previous dose immediately is often the most effective remedy.
However, they warn against "polypharmacy" (adding more drugs to treat withdrawal symptoms). In cases of protracted withdrawal—where symptoms persist for months or years—they recommend waiting for natural improvement rather than introducing new psychotropic drugs, which can often complicate the clinical picture.
Implications: Changing the Face of Primary Care
The implications of this research for primary care are profound. Because the majority of antidepressants are prescribed by General Practitioners (GPs) rather than psychiatrists, the responsibility for safe tapering falls on the shoulders of primary care physicians.
The Ethical Imperative of Drug Reviews
The authors of the Rennwald study conclude that GPs must conduct regular, rigorous drug reviews. They argue that long-term therapy should not be the default, but should be constantly re-evaluated against clinical guidelines to avoid "unnecessary and potentially harmful treatment."
The "Hyperbolic" Nature of Tapering
A critical takeaway for clinicians is the realization that tapering is not linear. Due to the way antidepressants bind to receptors in the brain (a hyperbolic curve), a small reduction in milligrams at a low dose can have a much larger impact on the brain than a large reduction at a high dose. This explains why the "75% of MED" threshold is so significant; it is the point where receptor occupancy begins to drop precipitously.
Empowering the Patient
Finally, this research shifts the power dynamic between the doctor and the patient. By acknowledging that symptom increases are often pharmacological withdrawal, the medical community validates the patient’s experience. This prevents the "gaslighting" effect where a patient feels their "illness" is incurable, when in reality, their body is simply reacting to the removal of a potent chemical.
As the Rennwald study moves toward peer review, it stands as a critical challenge to the status quo. It suggests that the "mental health crisis" of recurring depression may, in many cases, be a "tapering crisis"—one that can only be solved by slower, more compassionate, and scientifically informed deprescribing practices.
References:
- Rennwald, A., et al. (2026). Incidence of Antidepressant Withdrawal Reactions: A Prospective Longitudinal Cohort Study in Primary Care Patients.
- Horowitz, M., & Perry, T.L. (2026). Stopping antidepressants safely. African Journal of Primary Health Care & Family Medicine.
